专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2009151695A4 COMPOUNDS AND METHOD FOR REDUCING URIC ACID 审中-公开
标题翻译：化合物和减少尿酸的方法
公开(公告)号：WO2009151695A4
公开(公告)日：2010-03-04
申请号：PCT/US2009037128
申请日：2009-03-13
申请人： WELLSTAT THERAPEUTICS CORP , O'NEIL JAMES DENNEN , BAMAT MICHAEL K , VON BORSTEL REID W , SHARMA SHALINI , ARUDCHANDRAN RAMACHANDRAN
发明人： O'NEIL JAMES DENNEN , BAMAT MICHAEL K , VON BORSTEL REID W , SHARMA SHALINI , ARUDCHANDRAN RAMACHANDRAN
IPC分类号： A01N43/08
CPC分类号： C07C59/68 , A23G3/36 , A23G3/38 , A23G3/42 , A23G3/48 , A23G3/563 , A61K8/498 , A61K9/0056 , A61K31/192 , A61K31/216 , A61K31/352 , A61K31/704 , A61K45/06 , A61Q11/00 , C07C59/66 , C07C59/84 , C07C59/88 , C07C59/90 , C07C61/39 , C07C69/716 , C07C69/734 , C07C69/738 , C07C2601/02
摘要： Uric acid in mammalian subjects is reduced and excretion of uric acid is increased by administering a compound of Formula (I) or a pharmaceutically acceptable salt thereof. In Formula (I) m is 0, 1, 2, 3 or 4; n is 0 or 1; m + n is not more than 4; t is 0 or 1; q is 0 or 1; and r is 0, 1 or 2. R6 is hydrogen, methyl or ethyl and R12 is hydrogen or methyl, or R6 is hydroxy and R12 is hydrogen, or R6 is O and R12 is absent, or R6 and R12 together are -CH2CH2-. R7 is hydrogen or alkyl having from 1 to 3 carbon atoms. One of R8 and R9 is alkyl having from 1 to 3 carbon atoms, and the other is hydrogen or alkyl having from 1 to 3 carbon atoms. R10 is hydrogen, halo, alkyl having from 1 to 3 carbon atoms or alkoxy having from 1 to 3 carbon atoms. X is C(O) and r is 0 and t is 0; or X is NH(R11) wherein R11 is hydrogen or alkyl having from 1 to 3 carbon atoms. A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from halo, hydroxy, methyl, ethyl, perfluoromethyl, methoxy, ethoxy, and perfluoromethoxy; or a 5 or 6 membered heteroaromatic ring having 1 or 2 ring heteroatoms selected from N, S and O and the heteroaromatic ring is covalently bound to the remainder of the compound of Formula (I) by a ring carbon; or cycloalkyl having from 3 to 6 ring carbon atoms wherein the cycloalkyl is unsubstituted or one or two ring carbons are independently monosubstituted by methyl or ethyl. The uric acid-lowering effects of the Compounds of Formula (I) are used to treat or prevent a variety of conditions including gout, hyperuricemia, elevated levels of uric acid that do not meet the levels customarily justifying a diagnosis of hyperuricemia, renal dysfunction, kidney stones, cardiovascular disease, risk for developing cardiovascular disease, tumor-lysis syndrome, and cognitive impairment.
摘要翻译：通过施用式（I）的化合物或其药学上可接受的盐，减少哺乳动物受试者的尿酸并增加尿酸的排泄。式（I）中，m为0,1,2,3或4; n为0或1; m + n不大于4; t为0或1; q为0或1; R6是氢，甲基或乙基，R12是氢或甲基，或R6是羟基，R12是氢，或R6是O，R12不存在，或者R6和R12一起是-CH 2 CH 2 - 。 R7是氢或具有1至3个碳原子的烷基。 R8和R9中的一个是具有1至3个碳原子的烷基，另一个是氢或具有1至3个碳原子的烷基。 R 10是氢，卤素，具有1至3个碳原子的烷基或具有1至3个碳原子的烷氧基。 X为C（O），r为0且t为0; 或X是NH（R 11），其中R 11是氢或具有1至3个碳原子的烷基。 A是未取代或被1或2个选自卤素，羟基，甲基，乙基，全氟甲基，甲氧基，乙氧基和全氟甲氧基的基团取代的苯基; 或具有1或2个选自N，S和O的环杂原子的5或6元杂芳环，杂芳环通过环碳与式（I）化合物的其余部分共价结合; 或具有3至6个环碳原子的环烷基，其中环烷基是未取代的或一个或两个环碳原子被甲基或乙基独立地单取代。式（I）化合物的尿酸降低作用用于治疗或预防各种病症，包括痛风，高尿酸血症，升高的尿酸水平，不符合常规诊断为高尿酸血症，肾功能不全的水平，肾结石，心血管疾病，发生心血管疾病的风险，肿瘤溶解综合征和认知障碍。

2. 发明申请

WO2005013920A2 NEWCASTLE DISEASE VIRUS ADMINISTRATION 审中-公开
标题翻译：纽卡斯尔病毒病毒管理局
公开(公告)号：WO2005013920A2
公开(公告)日：2005-02-17
申请号：PCT/US2004006159
申请日：2004-03-02
申请人： WELLSTAT BIOLOGICS CORP , BAMAT MICHAEL K , LORENCE ROBERT M , MAJOR PIERRE P , RABIN EVELYN HF , ROBERTS MICHAEL S
发明人： BAMAT MICHAEL K , LORENCE ROBERT M , MAJOR PIERRE P , RABIN HARVEY DI , ROBERTS MICHAEL S
IPC分类号： A01N63/00 , A61K20060101 , A61K35/76 , A61K39/17 , A61K
CPC分类号： A61K35/768 , C12N2760/18132
摘要： A mammalian subject having a tumor is treated by a method comprising administering an effective amount of a Newcastle disease virus, wherein the virus is administered to the subject in one or more cycles; and at least one cycle comprises administering sequentially one or more initial doses of from 1.8 X 10 PFU to 4.8 X 10 PFU of the virus per square meter of patient surface area followed by administering one or more subsequent doses of from 2.4 X 10 PFU to 1.2 X 10 PFU of the virus per square meter of patient surface area.
摘要翻译：具有肿瘤的哺乳动物受试者通过包括施用有效量的新城疫病毒的方法进行治疗，其中所述病毒以一个或多个周期施用于受试者; 并且至少一个循环包括每平方米患者表面积依次施用1.8×10 10 PFU至4.8×10 10 PFU病毒的一种或多种初始剂量，然后施用一个或多个后续剂量的 2.4×10 10 PFU至1.2×10 11 PFU病毒每平方米患者表面积。

3. 发明申请

WO2009151695A1 COMPOUNDS AND METHOD FOR REDUCING URIC ACID 审中-公开
标题翻译：化合物和减少尿酸的方法
公开(公告)号：WO2009151695A1
公开(公告)日：2009-12-17
申请号：PCT/US2009/037128
申请日：2009-03-13
申请人： WELLSTAT THERAPEUTICS CORPORATION , O'NEIL, James, Dennen , BAMAT, Michael, K. , VON BORSTEL, Reid, W. , SHARMA, Shalini , ARUDCHANDRAN, Ramachandran
发明人： O'NEIL, James, Dennen , BAMAT, Michael, K. , VON BORSTEL, Reid, W. , SHARMA, Shalini , ARUDCHANDRAN, Ramachandran
IPC分类号： A01N43/08
CPC分类号： C07C59/68 , A23G3/36 , A23G3/38 , A23G3/42 , A23G3/48 , A23G3/563 , A61K8/498 , A61K9/0056 , A61K31/192 , A61K31/216 , A61K31/352 , A61K31/704 , A61K45/06 , A61Q11/00 , C07C59/66 , C07C59/84 , C07C59/88 , C07C59/90 , C07C61/39 , C07C69/716 , C07C69/734 , C07C69/738 , C07C2601/02
摘要： Uric acid in mammalian subjects is reduced and excretion of uric acid is increased by administering a compound of Formula (I) or a pharmaceutically acceptable salt thereof. In Formula (I) m is 0, 1, 2, 3 or 4; n is 0 or 1; m + n is not more than 4; t is 0 or 1; q is 0 or 1; and r is 0, 1 or 2. R 6 is hydrogen, methyl or ethyl and R 12 is hydrogen or methyl, or R 6 is hydroxy and R 12 is hydrogen, or R 6 is O and R 12 is absent, or R 6 and R 12 together are -CH 2 CH 2 -. R 7 is hydrogen or alkyl having from 1 to 3 carbon atoms. One of R 8 and R 9 is alkyl having from 1 to 3 carbon atoms, and the other is hydrogen or alkyl having from 1 to 3 carbon atoms. R 10 is hydrogen, halo, alkyl having from 1 to 3 carbon atoms or alkoxy having from 1 to 3 carbon atoms. X is C(O) and r is 0 and t is 0; or X is NH(R 11 ) wherein R 11 is hydrogen or alkyl having from 1 to 3 carbon atoms. A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from halo, hydroxy, methyl, ethyl, perfluoromethyl, methoxy, ethoxy, and perfluoromethoxy; or a 5 or 6 membered heteroaromatic ring having 1 or 2 ring heteroatoms selected from N, S and O and the heteroaromatic ring is covalently bound to the remainder of the compound of Formula (I) by a ring carbon; or cycloalkyl having from 3 to 6 ring carbon atoms wherein the cycloalkyl is unsubstituted or one or two ring carbons are independently monosubstituted by methyl or ethyl. The uric acid-lowering effects of the Compounds of Formula (I) are used to treat or prevent a variety of conditions including gout, hyperuricemia, elevated levels of uric acid that do not meet the levels customarily justifying a diagnosis of hyperuricemia, renal dysfunction, kidney stones, cardiovascular disease, risk for developing cardiovascular disease, tumor-lysis syndrome, and cognitive impairment.
摘要翻译：通过施用式（I）的化合物或其药学上可接受的盐，减少哺乳动物受试者的尿酸并增加尿酸的排泄。式（I）中，m为0,1,2,3或4; n为0或1; m + n不大于4; t为0或1; q为0或1; R6是氢，甲基或乙基，R12是氢或甲基，或R6是羟基，R12是氢，或R6是O，R12不存在，或者R6和R12一起是-CH 2 CH 2 - 。 R7是氢或具有1至3个碳原子的烷基。 R8和R9中的一个是具有1至3个碳原子的烷基，另一个是氢或具有1至3个碳原子的烷基。 R 10是氢，卤素，具有1至3个碳原子的烷基或具有1至3个碳原子的烷氧基。 X为C（O），r为0且t为0; 或X是NH（R 11），其中R 11是氢或具有1至3个碳原子的烷基。 A是未取代或被1或2个选自卤素，羟基，甲基，乙基，全氟甲基，甲氧基，乙氧基和全氟甲氧基的基团取代的苯基; 或具有1或2个选自N，S和O的环杂原子的5或6元杂芳环，杂芳环通过环碳与式（I）化合物的其余部分共价结合; 或具有3至6个环碳原子的环烷基，其中环烷基是未取代的或一个或两个环碳原子被甲基或乙基独立地单取代。式（I）化合物的尿酸降低作用用于治疗或预防各种病症，包括痛风，高尿酸血症，升高的尿酸水平，不符合常规诊断为高尿酸血症，肾功能不全的水平，肾结石，心血管疾病，发生心血管疾病的风险，肿瘤溶解综合征和认知障碍。

4. 发明申请

WO2005013920A3 NEWCASTLE DISEASE VIRUS ADMINISTRATION 审中-公开
公开(公告)号：WO2005013920A3
公开(公告)日：2005-02-17
申请号：PCT/US2004/006159
申请日：2004-03-02
申请人： WELLSTAT BIOLOGICS CORPORATION , RABIN, Evelyn , BAMAT, Michael, K. , LORENCE, Robert, M. , MAJOR, Pierre, P. , ROBERTS, Michael, S.
发明人： BAMAT, Michael, K. , LORENCE, Robert, M. , MAJOR, Pierre, P. , ROBERTS, Michael, S.
IPC分类号： A01N63/00
摘要： A mammalian subject having a tumor is treated by a method comprising administering an effective amount of a Newcastle disease virus, wherein the virus is administered to the subject in one or more cycles; and at least one cycle comprises administering sequentially one or more initial doses of from 1.8 X 10 10 PFU to 4.8 X 10 10 PFU of the virus per square meter of patient surface area followed by administering one or more subsequent doses of from 2.4 X 10 10 PFU to 1.2 X 10 11 PFU of the virus per square meter of patient surface area.

5. 发明申请

WO2002100341A3 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS 审中-公开
公开(公告)号：WO2002100341A3
公开(公告)日：2002-12-19
申请号：PCT/US2002/018388
申请日：2002-06-12
申请人： WELLSTAT THERAPEUTICS CORPORATION , SHARMA, Shalini , VON, Borstel, Reid, W. , HODGE, Kirvin, L. , BAMAT, Michael, K.
发明人： SHARMA, Shalini , VON, Borstel, Reid, W. , HODGE, Kirvin, L. , BAMAT, Michael, K.
IPC分类号： C07D249/12
摘要： Compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis, are disclosed.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式